{"entity":{"type":"insider","cik":"0001581754","url":"/insider/0001581754","json_url":"/insider/0001581754.json","name":"Tananbaum James B.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":72,"n_filings":33,"first":"2013-10-16","last":"2026-08-10","span_basis":"filed_date"},"name_variants":[{"name":"Tananbaum James B.","source":"filing","n_filings":33,"first_seen":"2013-10-16","last_seen":"2026-08-10"}],"transactions":[{"id":9292619,"accession":"0001581754-26-000006","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001581754-26-000006","line_url":"/filing/0001581754-26-000006#line-1","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"Latigo Biotherapeutics, Inc.","issuer_ticker":"LTGO","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":"0001581754","owner_name":"Tananbaum James B.","owner_display_name":"Tananbaum James B.","owner_url":"/insider/0001581754","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":140000.0,"shares_display":"140,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":2520000.0,"total_display":"2,520,000.00","total_whole":"2,520,000","shares_owned_after":2008024.0,"shares_owned_after_display":"2,008,024","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-10","filed_date":"2026-08-10","scope":"insider"},{"id":6014407,"accession":"0001104659-26-003016","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-26-003016","line_url":"/filing/0001104659-26-003016","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"ALUMIS INC.","issuer_ticker":"ALMS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":"0001581754","owner_name":"Tananbaum James B.","owner_display_name":"Tananbaum James B.","owner_url":"/insider/0001581754","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":411764.0,"shares_display":"411,764","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":6999988.0,"total_display":"6,999,988.00","total_whole":"6,999,988","shares_owned_after":2908332.0,"shares_owned_after_display":"2,908,332","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-08","filed_date":"2026-01-12","scope":"insider","n_lines":2},{"id":4327711,"accession":"0001104659-25-115950","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-115950","line_url":"/filing/0001104659-25-115950#line-1","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"ALUMIS INC.","issuer_ticker":"ALMS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":"0001581754","owner_name":"Tananbaum James B.","owner_display_name":"Tananbaum James B.","owner_url":"/insider/0001581754","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":72212.0,"shares_display":"72,212","price_per_share":7.38,"price_display":"7.38","price_state":"stated","total_value":532924.56,"total_display":"532,924.56","total_whole":"532,925","shares_owned_after":2614215.0,"shares_owned_after_display":"2,614,215","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-21","filed_date":"2025-11-25","scope":"insider"},{"id":4725816,"accession":"0001104659-25-114266","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-25-114266","line_url":"/filing/0001104659-25-114266#line-4","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"ALUMIS INC.","issuer_ticker":"ALMS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":"0001581754","owner_name":"Tananbaum James B.","owner_display_name":"Tananbaum James B.","owner_url":"/insider/0001581754","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":190500.0,"shares_display":"190,500","price_per_share":6.56,"price_display":"6.56","price_state":"stated","total_value":1249680.0,"total_display":"1,249,680.00","total_whole":"1,249,680","shares_owned_after":2542003.0,"shares_owned_after_display":"2,542,003","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-19","filed_date":"2025-11-19","scope":"insider"},{"id":4725812,"accession":"0001104659-25-114266","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-25-114266","line_url":"/filing/0001104659-25-114266#line-3","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"ALUMIS INC.","issuer_ticker":"ALMS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":"0001581754","owner_name":"Tananbaum James B.","owner_display_name":"Tananbaum James B.","owner_url":"/insider/0001581754","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":117374.0,"shares_display":"117,374","price_per_share":6.19,"price_display":"6.19","price_state":"stated","total_value":726545.06,"total_display":"726,545.06","total_whole":"726,545","shares_owned_after":2351503.0,"shares_owned_after_display":"2,351,503","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-18","filed_date":"2025-11-19","scope":"insider"},{"id":4725807,"accession":"0001104659-25-114266","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-25-114266","line_url":"/filing/0001104659-25-114266","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"ALUMIS INC.","issuer_ticker":"ALMS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":"0001581754","owner_name":"Tananbaum James B.","owner_display_name":"Tananbaum James B.","owner_url":"/insider/0001581754","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":5.5925,"price_display":"5.59","price_state":"stated","total_value":1118500.0,"total_display":"1,118,500.00","total_whole":"1,118,500","shares_owned_after":2234129.0,"shares_owned_after_display":"2,234,129","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-17","filed_date":"2025-11-19","scope":"insider","n_lines":2},{"id":4391977,"accession":"0001104659-25-045222","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-25-045222","line_url":"/filing/0001104659-25-045222#line-2","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"ALUMIS INC.","issuer_ticker":"ALMS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":"0001581754","owner_name":"Tananbaum James B.","owner_display_name":"Tananbaum James B.","owner_url":"/insider/0001581754","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":4.34,"price_display":"4.34","price_state":"stated","total_value":86800.0,"total_display":"86,800.00","total_whole":"86,800","shares_owned_after":4247670.0,"shares_owned_after_display":"4,247,670","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-06","filed_date":"2025-05-06","scope":"insider"},{"id":4391974,"accession":"0001104659-25-045222","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-045222","line_url":"/filing/0001104659-25-045222#line-1","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"ALUMIS INC.","issuer_ticker":"ALMS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":"0001581754","owner_name":"Tananbaum James B.","owner_display_name":"Tananbaum James B.","owner_url":"/insider/0001581754","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":4.62,"price_display":"4.62","price_state":"stated","total_value":115500.0,"total_display":"115,500.00","total_whole":"115,500","shares_owned_after":4227670.0,"shares_owned_after_display":"4,227,670","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-02","filed_date":"2025-05-06","scope":"insider"},{"id":2538042,"accession":"0001104659-24-077875","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001104659-24-077875","line_url":"/filing/0001104659-24-077875","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"ALUMIS INC.","issuer_ticker":"ALMS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":"0001581754","owner_name":"Tananbaum James B.","owner_display_name":"Tananbaum James B.","owner_url":"/insider/0001581754","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500000.0,"shares_display":"2,500,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":40000000.0,"total_display":"40,000,000.00","total_whole":"40,000,000","shares_owned_after":4202670.0,"shares_owned_after_display":"4,202,670","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-07-01","filed_date":"2024-07-03","scope":"insider","n_lines":2},{"id":8703834,"accession":"0001209191-23-042720","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-042720","line_url":"/filing/0001209191-23-042720","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"Theseus Pharmaceuticals, Inc.","issuer_ticker":"THRX","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Management V, LLC; Foresite Capital Opportunity Management V, LLC; Foresite Capital Fund V, L.P.","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":700000.0,"shares_display":"700,000","price_per_share":2.97,"price_display":"2.97","price_state":"stated","total_value":2079000.0,"total_display":"2,079,000.00","total_whole":"2,079,000","shares_owned_after":4108796.0,"shares_owned_after_display":"4,108,796","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-17","filed_date":"2023-07-19","scope":"insider","n_lines":2},{"id":8468626,"accession":"0001209191-23-028537","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-028537","line_url":"/filing/0001209191-23-028537","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"Kinnate Biopharma Inc.","issuer_ticker":"KNTE","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":"0001581754","owner_name":"Tananbaum James B.","owner_display_name":"Tananbaum James B.","owner_url":"/insider/0001581754","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1780000.0,"shares_display":"1,780,000","price_per_share":2.8,"price_display":"2.80","price_state":"stated","total_value":4984000.0,"total_display":"4,984,000.00","total_whole":"4,984,000","shares_owned_after":3525957.0,"shares_owned_after_display":"3,525,957","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-08","filed_date":"2023-05-10","scope":"insider","n_lines":2},{"id":8585798,"accession":"0001213900-23-028117","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-23-028117","line_url":"/filing/0001213900-23-028117#line-1","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"PARDES BIOSCIENCES, INC.","issuer_ticker":"PRDS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Opportunity Management V, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":773952.0,"shares_display":"773,952","price_per_share":1.5,"price_display":"1.50","price_state":"stated","total_value":1160928.0,"total_display":"1,160,928.00","total_whole":"1,160,928","shares_owned_after":8773134.0,"shares_owned_after_display":"8,773,134","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-05","filed_date":"2023-04-06","scope":"insider"},{"id":8079891,"accession":"0001213900-23-028116","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-23-028116","line_url":"/filing/0001213900-23-028116#line-1","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"PARDES BIOSCIENCES, INC.","issuer_ticker":"PRDS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Management V, LLC; Foresite Capital Fund V, L.P.","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":773952.0,"shares_display":"773,952","price_per_share":1.5,"price_display":"1.50","price_state":"stated","total_value":1160928.0,"total_display":"1,160,928.00","total_whole":"1,160,928","shares_owned_after":13583762.0,"shares_owned_after_display":"13,583,762","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-05","filed_date":"2023-04-06","scope":"insider"},{"id":8626788,"accession":"0001209191-23-000204","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-000204","line_url":"/filing/0001209191-23-000204","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"Theseus Pharmaceuticals, Inc.","issuer_ticker":"THRX","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":null,"owner_name":"Foresite Capital Fund V, L.P.; Tananbaum James B.; Foresite Capital Management V, LLC; Foresite Capital Opportunity Management V, LLC; Foresite Capital Opportunity Fund V, L.P.","owner_display_name":"Foresite Capital Fund V, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":2500000.0,"total_display":"2,500,000.00","total_whole":"2,500,000","shares_owned_after":3585346.0,"shares_owned_after_display":"3,585,346","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-29","filed_date":"2023-01-03","scope":"insider","n_lines":2},{"id":6466708,"accession":"0001213900-22-077637","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-22-077637","line_url":"/filing/0001213900-22-077637#line-1","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"PARDES BIOSCIENCES, INC.","issuer_ticker":"PRDS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":null,"owner_name":"Foresite Capital Fund V, L.P.; Foresite Capital Management V, LLC; Tananbaum James B.","owner_display_name":"Foresite Capital Fund V, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":637420.0,"shares_display":"637,420","price_per_share":0.85,"price_display":"0.85","price_state":"stated","total_value":541807.0,"total_display":"541,807.00","total_whole":"541,807","shares_owned_after":12809810.0,"shares_owned_after_display":"12,809,810","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-01","filed_date":"2022-12-05","scope":"insider"},{"id":4748044,"accession":"0001213900-21-067341","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-21-067341","line_url":"/filing/0001213900-21-067341#line-1","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"PARDES BIOSCIENCES, INC.","issuer_ticker":"PRDS","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":null,"owner_name":"Foresite Capital Management V, LLC; Foresite Capital Opportunity Management V, LLC; Foresite Capital Fund V, L.P.; Foresite Capital Opportunity Fund V, L.P.; Tananbaum James B.","owner_display_name":"Foresite Capital Management V, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":325000.0,"shares_display":"325,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":3250000.0,"total_display":"3,250,000.00","total_whole":"3,250,000","shares_owned_after":325000.0,"shares_owned_after_display":"325,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-12-22","filed_date":"2021-12-23","scope":"insider"},{"id":4239195,"accession":"0001213900-21-011174","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-21-011174","line_url":"/filing/0001213900-21-011174#line-1","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"FS Development Corp. II","issuer_ticker":"FSII","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":null,"owner_name":"Foresite Capital Fund V, L.P.; Tananbaum James B.; FS Development Holdings II, LLC; Foresite Capital Management V, LLC","owner_display_name":"Foresite Capital Fund V, L.P.","owner_url":null,"role":"Director, Officer (President & CEO), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":"President & CEO","security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":602500.0,"shares_display":"602,500","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":6025000.0,"total_display":"6,025,000.00","total_whole":"6,025,000","shares_owned_after":602500.0,"shares_owned_after_display":"602,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-19","filed_date":"2021-02-23","scope":"insider"},{"id":2972734,"accession":"0001140361-20-027407","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-20-027407","line_url":"/filing/0001140361-20-027407","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"Kinnate Biopharma Inc.","issuer_ticker":"KNTE","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":"0001581754","owner_name":"Tananbaum James B.","owner_display_name":"Tananbaum James B.","owner_url":"/insider/0001581754","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000000.0,"shares_display":"1,000,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":20000000.0,"total_display":"20,000,000.00","total_whole":"20,000,000","shares_owned_after":500000.0,"shares_owned_after_display":"500,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-03","filed_date":"2020-12-04","scope":"insider","n_lines":3},{"id":2692628,"accession":"0001213900-20-032139","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-20-032139","line_url":"/filing/0001213900-20-032139#line-1","is_derivative":false,"issuer_cik":"0001581754","issuer_name":"FS Development Corp.","issuer_ticker":"FSDC","issuer_name_source":null,"issuer_url":"/issuer/0001581754","owner_cik":null,"owner_name":"Foresite Capital Fund V, L.P.; Foresite Capital Management V, LLC; FS Development Holdings, LLC; Tananbaum James B.","owner_display_name":"Foresite Capital Fund V, L.P.","owner_url":null,"role":"Director, Officer (President & CEO), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":"President & CEO","security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":441500.0,"shares_display":"441,500","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":4415000.0,"total_display":"4,415,000.00","total_whole":"4,415,000","shares_owned_after":441500.0,"shares_owned_after_display":"441,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-14","filed_date":"2020-10-19","scope":"insider"},{"id":2039810,"accession":"0000899243-20-013113","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-013113","line_url":"/filing/0000899243-20-013113","is_derivative":false,"issuer_cik":"0001562157","issuer_name":"10x Genomics, Inc.","issuer_ticker":"TXG","issuer_name_source":null,"issuer_url":"/issuer/0001562157","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Management I, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund I, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1450000.0,"shares_display":"1,450,000","price_per_share":80.13,"price_display":"80.13","price_state":"stated","total_value":116188500.0,"total_display":"116,188,500.00","total_whole":"116,188,500","shares_owned_after":3500000.0,"shares_owned_after_display":"3,500,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-13","filed_date":"2020-05-14","scope":"insider","n_lines":2},{"id":2244463,"accession":"0000899243-20-009021","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-009021","line_url":"/filing/0000899243-20-009021","is_derivative":false,"issuer_cik":"0001562157","issuer_name":"10x Genomics, Inc.","issuer_ticker":"TXG","issuer_name_source":null,"issuer_url":"/issuer/0001562157","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Management I, LLC; Foresite Capital Fund I, L.P.","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":750000.0,"shares_display":"750,000","price_per_share":59.0,"price_display":"59.00","price_state":"stated","total_value":44250000.0,"total_display":"44,250,000.00","total_whole":"44,250,000","shares_owned_after":1134579.0,"shares_owned_after_display":"1,134,579","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-17","filed_date":"2020-03-19","scope":"insider","n_lines":2},{"id":2138464,"accession":"0001209191-20-014562","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-014562","line_url":"/filing/0001209191-20-014562","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Fund IV, L.P.; Tananbaum James B.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.","owner_display_name":"Foresite Capital Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000000.0,"shares_display":"1,000,000","price_per_share":17.07,"price_display":"17.07","price_state":"stated","total_value":17070000.0,"total_display":"17,070,000.00","total_whole":"17,070,000","shares_owned_after":1925020.0,"shares_owned_after_display":"1,925,020","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-27","filed_date":"2020-03-02","scope":"insider","n_lines":3},{"id":8647388,"accession":"0001209191-19-049680","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-049680","line_url":"/filing/0001209191-19-049680#line-1","is_derivative":false,"issuer_cik":"0001562157","issuer_name":"10x Genomics, Inc.","issuer_ticker":"TXG","issuer_name_source":null,"issuer_url":"/issuer/0001562157","owner_cik":null,"owner_name":"Foresite Capital Fund II, L.P.; Foresite Capital Management I, LLC; Tananbaum James B.; Foresite Capital Management II, LLC; Foresite Capital Fund I, L.P.","owner_display_name":"Foresite Capital Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":187500.0,"shares_display":"187,500","price_per_share":39.0,"price_display":"39.00","price_state":"stated","total_value":7312500.0,"total_display":"7,312,500.00","total_whole":"7,312,500","shares_owned_after":187500.0,"shares_owned_after_display":"187,500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-09-12","filed_date":"2019-09-16","scope":"insider"},{"id":8120795,"accession":"0001209191-19-048830","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-048830","line_url":"/filing/0001209191-19-048830#line-3","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15700.0,"shares_display":"15,700","price_per_share":18.42,"price_display":"18.42","price_state":"stated","total_value":289194.0,"total_display":"289,194.00","total_whole":"289,194","shares_owned_after":2350477.0,"shares_owned_after_display":"2,350,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-09-05","filed_date":"2019-09-06","scope":"insider"},{"id":8120792,"accession":"0001209191-19-048830","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-048830","line_url":"/filing/0001209191-19-048830","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100200.0,"shares_display":"100,200","price_per_share":18.48,"price_display":"18.48","price_state":"stated","total_value":1851696.0,"total_display":"1,851,696.00","total_whole":"1,851,696","shares_owned_after":1400900.0,"shares_owned_after_display":"1,400,900","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-09-04","filed_date":"2019-09-06","scope":"insider","n_lines":2},{"id":8102225,"accession":"0001209191-19-048394","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-048394","line_url":"/filing/0001209191-19-048394","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Tananbaum James B.","owner_display_name":"Foresite Capital Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":20.81482,"price_display":"20.81","price_state":"stated","total_value":1040741.0,"total_display":"1,040,741.00","total_whole":"1,040,741","shares_owned_after":2310377.0,"shares_owned_after_display":"2,310,377","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-09-03","filed_date":"2019-09-04","scope":"insider","n_lines":2},{"id":8102213,"accession":"0001209191-19-048394","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-048394","line_url":"/filing/0001209191-19-048394#line-1","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Management II, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Tananbaum James B.","owner_display_name":"Foresite Capital Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":21.36,"price_display":"21.36","price_state":"stated","total_value":534000.0,"total_display":"534,000.00","total_whole":"534,000","shares_owned_after":2275477.0,"shares_owned_after_display":"2,275,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-30","filed_date":"2019-09-04","scope":"insider"},{"id":8027908,"accession":"0001209191-19-047387","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-047387","line_url":"/filing/0001209191-19-047387#line-3","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":38300.0,"shares_display":"38,300","price_per_share":23.42,"price_display":"23.42","price_state":"stated","total_value":896986.0,"total_display":"896,986.00","total_whole":"896,986","shares_owned_after":2250477.0,"shares_owned_after_display":"2,250,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-23","filed_date":"2019-08-23","scope":"insider"},{"id":8027907,"accession":"0001209191-19-047387","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-047387","line_url":"/filing/0001209191-19-047387#line-2","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6700.0,"shares_display":"6,700","price_per_share":23.68,"price_display":"23.68","price_state":"stated","total_value":158656.0,"total_display":"158,656.00","total_whole":"158,656","shares_owned_after":2212177.0,"shares_owned_after_display":"2,212,177","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-22","filed_date":"2019-08-23","scope":"insider"},{"id":8027902,"accession":"0001209191-19-047387","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-047387","line_url":"/filing/0001209191-19-047387#line-1","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1153.0,"shares_display":"1,153","price_per_share":23.25,"price_display":"23.25","price_state":"stated","total_value":26807.25,"total_display":"26,807.25","total_whole":"26,807","shares_owned_after":2205477.0,"shares_owned_after_display":"2,205,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-21","filed_date":"2019-08-23","scope":"insider"},{"id":8120433,"accession":"0001209191-19-046913","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-046913","line_url":"/filing/0001209191-19-046913#line-3","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Management II, LLC; Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.","owner_display_name":"Foresite Capital Management III, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":23.21,"price_display":"23.21","price_state":"stated","total_value":1160500.0,"total_display":"1,160,500.00","total_whole":"1,160,500","shares_owned_after":2204324.0,"shares_owned_after_display":"2,204,324","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-20","filed_date":"2019-08-20","scope":"insider"},{"id":8120430,"accession":"0001209191-19-046913","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-046913","line_url":"/filing/0001209191-19-046913#line-2","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Management II, LLC; Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.","owner_display_name":"Foresite Capital Management III, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3847.0,"shares_display":"3,847","price_per_share":23.34,"price_display":"23.34","price_state":"stated","total_value":89788.98,"total_display":"89,788.98","total_whole":"89,789","shares_owned_after":2154324.0,"shares_owned_after_display":"2,154,324","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-19","filed_date":"2019-08-20","scope":"insider"},{"id":8120427,"accession":"0001209191-19-046913","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-046913","line_url":"/filing/0001209191-19-046913#line-1","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Management II, LLC; Tananbaum James B.; Foresite Capital Fund IV, L.P.; Foresite Capital Fund II, L.P.; Foresite Capital Fund III, L.P.","owner_display_name":"Foresite Capital Management III, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":24.23,"price_display":"24.23","price_state":"stated","total_value":2423000.0,"total_display":"2,423,000.00","total_whole":"2,423,000","shares_owned_after":2150477.0,"shares_owned_after_display":"2,150,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-16","filed_date":"2019-08-20","scope":"insider"},{"id":8568332,"accession":"0001209191-19-046012","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-046012","line_url":"/filing/0001209191-19-046012#line-4","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund II, L.P.; Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":23.73,"price_display":"23.73","price_state":"stated","total_value":2373000.0,"total_display":"2,373,000.00","total_whole":"2,373,000","shares_owned_after":2050477.0,"shares_owned_after_display":"2,050,477","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-14","filed_date":"2019-08-14","scope":"insider"},{"id":8568328,"accession":"0001209191-19-046012","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-046012","line_url":"/filing/0001209191-19-046012","is_derivative":false,"issuer_cik":"0001337553","issuer_name":"AERIE PHARMACEUTICALS INC","issuer_ticker":"AERI","issuer_name_source":null,"issuer_url":"/issuer/0001337553","owner_cik":null,"owner_name":"Tananbaum James B.; Foresite Capital Fund II, L.P.; Foresite Capital Fund IV, L.P.; Foresite Capital Management III, LLC; Foresite Capital Management IV, LLC; Foresite Capital Fund III, L.P.; Foresite Capital Management II, LLC","owner_display_name":"Tananbaum James B.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":25.3493672,"price_display":"25.35","price_state":"stated","total_value":6337341.8,"total_display":"6,337,341.80","total_whole":"6,337,342","shares_owned_after":1310000.0,"shares_owned_after_display":"1,310,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-13","filed_date":"2019-08-14","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":"2019-08-13|8568325","ledger_fault":false,"count":{"value":17,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":17,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":17},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002056611","name":"Latigo Biotherapeutics, Inc.","url":"/issuer/0002056611","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2026-08-10","last_seen":"2026-08-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001847367","name":"ALUMIS INC.","url":"/issuer/0001847367","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2024-07-03","last_seen":"2026-01-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001745020","name":"Theseus Pharmaceuticals, Inc.","url":"/issuer/0001745020","role":"Ten percent owner","n_filings":2,"first_seen":"2023-01-03","last_seen":"2023-07-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001797768","name":"Kinnate Biopharma Inc.","url":"/issuer/0001797768","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2020-12-04","last_seen":"2023-05-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001822711","name":"PARDES BIOSCIENCES, INC.","url":"/issuer/0001822711","role":"Director, Officer (President & CEO), Ten percent owner","n_filings":5,"first_seen":"2021-02-23","last_seen":"2023-04-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001816736","name":"FS Development Corp.","url":"/issuer/0001816736","role":"Director, Officer (President & CEO), Ten percent owner","n_filings":1,"first_seen":"2020-10-19","last_seen":"2020-10-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001770787","name":"10x Genomics, Inc.","url":"/issuer/0001770787","role":"Ten percent owner","n_filings":3,"first_seen":"2019-09-16","last_seen":"2020-05-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001337553","name":"AERIE PHARMACEUTICALS INC","url":"/issuer/0001337553","role":"Ten percent owner","n_filings":10,"first_seen":"2016-07-26","last_seen":"2020-03-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001631650","name":"Aimmune Therapeutics, Inc.","url":"/issuer/0001631650","role":"Ten percent owner","n_filings":3,"first_seen":"2015-08-11","last_seen":"2016-06-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001131543","name":"AMBIT BIOSCIENCES CORP","url":"/issuer/0001131543","role":"Ten percent owner","n_filings":1,"first_seen":"2013-10-16","last_seen":"2013-10-16"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001581754","retrieved_at":"2026-08-26T22:12:43+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}